Sarsia

Heimdall Power AS, established in Bergen, Norway in 2015, specializes in developing innovative sensor platforms for power grids. Their flagship product, Neuron, monitors transmission lines and distribution feeders in real-time, providing situational awareness through features such as line monitoring, fault detection, dynamic line rating, and advanced analytics. By installing these sensors on power lines to collect data on parameters like temperature, load, and line sag, Heimdall Power enables grid owners to optimize operations, enhance reliability, facilitate the transition to renewable energy sources, and ultimately improve overall grid performance.

Cetasol is an innovative technology firm focusing on intelligent solutions for sustainability in marine sector. It helps in decision-making, timesaving, emission reduction, and more. They provide solutions to enhance maritime operations and services for consultant improvements.

Calluna Pharma is a clinical-stage company focused on developing innovative therapies that leverage the body's immune system to treat various immunological diseases. The company has established a strong pipeline of selective antibodies aimed at addressing unmet clinical needs across a range of conditions. Its approach includes precision targeting of upstream innate immune amplifiers and the disruption of disease-associated downstream signaling pathways, all while ensuring a favorable safety profile for its therapeutic candidates. Through its research and development efforts, Calluna Pharma aims to transform treatment options for patients suffering from immunological disorders.

Heimdall Power AS, established in Bergen, Norway in 2015, specializes in developing innovative sensor platforms for power grids. Their flagship product, Neuron, monitors transmission lines and distribution feeders in real-time, providing situational awareness through features such as line monitoring, fault detection, dynamic line rating, and advanced analytics. By installing these sensors on power lines to collect data on parameters like temperature, load, and line sag, Heimdall Power enables grid owners to optimize operations, enhance reliability, facilitate the transition to renewable energy sources, and ultimately improve overall grid performance.

Sonoclear AS, founded in 2016 and based in Trondheim, Norway, specializes in the manufacturing of SonoClear®, an acoustic coupling fluid designed for brain tumor surgery. This innovative product enhances ultrasound imaging by eliminating image artifacts that typically occur in resection cavities. By improving the clarity of surgical images, SonoClear® supports healthcare professionals in making informed clinical decisions during procedures. The company is focused on advancing surgical techniques and outcomes in the field of neurosurgery through its specialized technology.

BerGenBio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for aggressive cancers. The company's lead drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical trials, including a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). In addition to its oncology focus, bemcentinib is also being explored in preclinical development for severe respiratory infections. Through its research, BerGenBio aims to address significant unmet medical needs in oncology and other serious diseases.

APIM Therapeutics AS, founded in 2009 and based in Trondheim, Norway, is dedicated to developing innovative therapies for cancer treatment. The company focuses on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA), a crucial protein involved in DNA repair and cellular responses to stress. By targeting the interactions between PCNA and specific proteins, APIM Therapeutics aims to enhance the efficacy of cancer treatments and improve patient outcomes. Their lead compound, ATX-101, has demonstrated proof-of-concept in various preclinical cancer models, highlighting its potential in combating cancer cells. Through its research and development efforts, APIM Therapeutics is positioned to contribute significantly to the field of oncology.

BerGenBio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for aggressive cancers. The company's lead drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical trials, including a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). In addition to its oncology focus, bemcentinib is also being explored in preclinical development for severe respiratory infections. Through its research, BerGenBio aims to address significant unmet medical needs in oncology and other serious diseases.

APIM Therapeutics AS, founded in 2009 and based in Trondheim, Norway, is dedicated to developing innovative therapies for cancer treatment. The company focuses on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA), a crucial protein involved in DNA repair and cellular responses to stress. By targeting the interactions between PCNA and specific proteins, APIM Therapeutics aims to enhance the efficacy of cancer treatments and improve patient outcomes. Their lead compound, ATX-101, has demonstrated proof-of-concept in various preclinical cancer models, highlighting its potential in combating cancer cells. Through its research and development efforts, APIM Therapeutics is positioned to contribute significantly to the field of oncology.

BerGenBio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for aggressive cancers. The company's lead drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical trials, including a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). In addition to its oncology focus, bemcentinib is also being explored in preclinical development for severe respiratory infections. Through its research, BerGenBio aims to address significant unmet medical needs in oncology and other serious diseases.

Isentio, established in 2014 and headquartered in Santa Cruz, California, specializes in developing and providing cloud-based SaaS solutions for infection intelligence. Its flagship product, RipSeq, significantly enhances the bacterial identification process by leveraging advanced DNA analysis methods. RipSeq is an online software tool designed to quickly identify bacteria in clinical samples, even when multiple bacteria are present, thereby reducing the time from sample to report by days.

Avexxin's therapeutic approach is built on more than a decade of research into the biological mechanisms involved in inflammatory diseases at the Norwegian University of Science and Technology. Avexxin's goal is to create a therapeutic company based on the discovery and development of novel therapeutics that address the fundamental mechanisms involved in inflammatory diseases.

WindSim AS is a company based in Tonsberg, Norway, specializing in software for simulating wind resources in complex terrains. It offers a product known as WindSim, which optimizes energy production from wind turbines across Europe, Asia, Australia, and North America. The software leverages advanced computational fluid dynamics and automated deep neural learning technologies to enhance the efficiency of energy projects by accurately forecasting energy production. In addition to its software solutions, WindSim provides consulting and training services to help clients effectively utilize its products. The company's offerings are distributed in various countries, including China, France, Germany, Italy, Spain, and Taiwan. WindSim AS was previously named VECTOR AS before adopting its current name in December 2005.